A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention (Q57774051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

G F Guzauskas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

S M Bradley

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

D L Veenstra

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

28 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

829-837

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22453194%20AND%20SRC:MED&resulttype=core&format=json

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Durability of platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Stakeholder perspectives on a risk-benefit framework for genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Preference-Based EQ-5D index scores for chronic conditions in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Economic notes. Discounting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021

What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.303

7 January 2021